Cardiff Oncology CRDF 深 滬
等待開盤 09-17 09:30:00 美东时间
1.35
+0.010
+0.75%
華盛通- 最 高1.38
- 今 開1.35
- 成交量 185.19万股
- 最 低 1.31
- 昨 收 1.34
- 總市值 1.05亿
- 52周最高 3.31
- 市盈率 靜 --
- 換手率 2.38%
- 52周最低 0.7566
- 委 比 -84.39%
- 總股本 7779.52万
- 歷史最高 977.76
- 量 比 1.28
- 振 幅 5.22%
- 歷史最低 0.701
- 每 手 1
- 風險率 0.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
HC Wainwright & Co. Upgrades Cardiff Oncology to Buy, Announces $9 Price Target
HC Wainwright & Co. analyst Robert Burns upgrades Cardiff Oncology (NASDAQ:CRDF) from Neutral to Buy and announces $9 price target.
09-15 18:28
Cardiff Oncology Amends Onvansertib License, Resolves Litigation
Cardiff Oncology ( ($CRDF) ) has shared an announcement. On September 14, 2026,...
09-14 21:47
Cardiff Oncology to Participate in September 2026 Conferences
Cardiff Oncology announced that Dr. Mani Mohindru will participate in two upcoming conferences: the 8th Annual RAS-Targeted Drug Development Summit on September 8, discussing PLK1-targeted therapy for RAS mutant metastatic colorectal cancer, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14, featuring a fireside chat. Slides and webcast access will be available on the company's website post-conference. Cardiff Oncol...
09-02 11:00
William Blair Downgrades Cardiff Oncology to Market Perform
William Blair analyst Andy Hsieh downgrades Cardiff Oncology (NASDAQ:CRDF) from Outperform to Market Perform.
08-13 03:03
Cardiff Oncology Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $104.000K Beat $70.714K Estimate
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 33.33 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $104.000 thous...
08-12 04:40
美股大行评级 | 火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元
火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元；犹他美容(ULTA)惨遭12家大行下调目标价>>
06-04 11:36
NMS Informs Cardiff Oncology Of Agreement Termination On May 27, 2026; NMS Alleges Cardiff Oncology Breached Agreement Over Cardiff Patents Inventorship; NMS Alleges Failure By Cardiff Oncology To Use Commercially Reasonable Efforts For Onvansertib; Cardiff Oncology States NMS Termination Notice Is Ineffective And Will Continue Under Agreement
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001213037/000119312526248711/crdf-20260527.htm
05-30 05:16
Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense
Cardiff Oncology sued Nerviano Medical Sciences over onvansertib licensing claims as analysts backed Cardiff's legal stance.
05-21 02:11
Cardiff Oncology Q1 EPS $(0.18) Misses $(0.15) Estimate, Sales $41.000K Miss $85.000K Estimate
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.15) by 20 percent. This is a 10 percent increase over losses of $(0.20) per share from the
05-15 04:59
